Back to results
US 10,478,405 B2Granted
Method for treating post-traumatic stress disorder
AssigneeIcahn School of Medicine at Mount Sinai
InventorsDennis S. Charney, Adriana Feder
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeIcahn School of Medicine at Mount Sinai
InventorsDennis S. Charney, Adriana Feder
Estimating the term…
The present disclosure provides compositions containing ketamine and methods of using those compositions for the treatment of post-traumatic stress disorder. Also provided herein is a pharmaceutical composition that comprises esketamine and a pharmaceutically acceptable carrier, excipient or diluent, for use in treatment of PTSD. In some aspects, the pharmaceutical composition is for intranasal or intravenous administration. In some aspects, the pharmaceutical composition is for use in a method of treating PTSD in a subject. In some aspects, the pharmaceutical composition is for use in a method of treating major depressive disorder in a subject that is co-morbid with the PTSD.
A method of treating post-traumatic stress disorder (PTSD) in a patient determined to be suffering from PTSD, comprising conducting a psychiatric evaluation of a patient to determine if the patient is afflicted with PTSD, and intranasally administering to a patient determined to be suffering from PTSD multiple sub-analgesic therapeutic doses of ketamine of between about 0.01 to about 3.0 mg of ketamine per kilogram of body weight of the patient (mg/kg).
A method of treating post-traumatic stress disorder (PTSD) in a patient determined to be suffering from PTSD, comprising administering to a human individual suffering from PTSD a first therapeutically effective amount of ketamine between about 0.01 to about 3.0 mg of ketamine per kilogram of body weight of the patient (mg/kg) and then administering to the individual a second therapeutically effective amount of ketamine, wherein the second therapeutically effective amount of ketamine is lower or higher than the first therapeutically effective amount of ketamine.
A method of treating post-traumatic stress disorder (PTSD) in a patient determined to be suffering from PTSD, comprising administering to a human individual suffering from PTSD a first therapeutically effective amount of ketamine between about 0.01 to about 3.0 mg of ketamine per kilogram of body weight of the patient (mg/kg), measuring the efficacy of the treatment in relieving the symptoms of PTSD after the administering step and, provided that one or more symptoms of PTSD or a comorbid depressive condition are alleviated, administering to the individual a second therapeutically effective amount of ketamine, wherein the second therapeutically effective amount of ketamine is lower or higher than the first therapeutically effective amount of ketamine.
A method of treating post-traumatic stress disorder (PTSD) in a patient determined to be suffering from acute symptoms of PTSD, comprising administering to a human individual suffering from acute symptoms of PTSD a first therapeutically effective amount of ketamine to treat said acute symptoms and thereafter administering to the individual a second lower amount of ketamine to treat chronic symptoms of PTSD.
A method of treating post-traumatic stress disorder (PTSD) in a patient determined to be suffering from PTSD, comprising administering to a human individual suffering from PTSD a first therapeutically effective amount of ketamine between about 0.01 to about 3.0 mg of ketamine per kilogram of body weight of the patient (mg/kg), measuring the efficacy of the treatment in relieving the symptoms of PTSD after the administering step and, provided that one or more symptoms of PTSD or a comorbid depressive condition are alleviated, administering to the individual a second therapeutically effective amount of ketamine.
Dependencies are inferred from the claim text.